Lirilumab (anti-KIR mAb) Combined with Rituximab for Relapsed, Refractory or High-risk Untreated Patients with Chronic Lymphocytic Leukemia (CLL)
The goal of this clinical research study is to learn if lirilumab in combination with rituximab can help to control either CLL or SLL. The safety of the drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 06/23/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: